Biosino Bio-Technology and Science Incorporation Valuation
Is 8247 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8247 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 8247's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 8247's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8247?
Other financial metrics that can be useful for relative valuation.
| What is 8247's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -25.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 8247's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.1x | ||
6628 Transcenta Holding | 15.9x | 67.8% | HK$380.8m |
1228 CANbridge Pharmaceuticals | 0.9x | n/a | HK$97.7m |
2197 Clover Biopharmaceuticals | 13x | n/a | HK$408.6m |
8158 China Regenerative Medicine International | 2.5x | n/a | HK$130.8m |
8247 Biosino Bio-Technology and Science Incorporation | 0.4x | n/a | HK$115.8m |
Price-To-Sales vs Peers: 8247 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (8x).
Price to Earnings Ratio vs Industry
How does 8247's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs Industry: 8247 is good value based on its Price-To-Sales Ratio (0.4x) compared to the Hong Kong Biotechs industry average (13.4x).
Price to Sales Ratio vs Fair Ratio
What is 8247's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8247's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.